merged_ftc-pharmacy-benefit-managers-drug-prices.txt
<question_number>1</question_number>
<answer>N/A</answer>
<other>The article does not mention the FTC deciding to bring a lawsuit against pharmacy benefit managers. It only states that the FTC issued a critical report, which could potentially lead to a formal investigation or lawsuit in the future.</other>

<question_number>2</question_number>
<answer>N/A</answer>
<other>The article does not provide information on when CVS Health acquired Caremark. It only mentions that by the end of 2018, each of the top three benefit managers had become part of the same company as a giant insurer.</other>

<question_number>3</question_number>
<answer>N/A</answer>
<other>The article does not provide a specific estimate of how much patients overpaid for generic drugs. It mentions that benefit managers' practices resulted in nearly $1.6 billion in revenue over less than three years for the biggest three conglomerates, but this figure relates to revenue, not specifically to patient overpayments.</other>